Jul. 21 at 5:08 PM
$MSLE should be trading at
$55/share.
Was investigating the stock a bit more. contextually, i believe this will be ready for accelerated approval, together with orphan drug.
i also saw a letter about
$CAPR adcom where the physician scientists arguedthe intended primary for the HOPE ph3 being upper limb function (PUL) and not to be hypercritical about the deramiocel data on cardiomyopathy.
if we compare the current status of these two drugs purely along this axis of upper limb function, where deramiocel does not actually regenerate muscle but SAT-3247 does, i see no reason why Satellos could not be trading at similar levels to CAPR (1.1bn mkcap).
that is a 6.32x premium from here.
$8.75 x 6.32 =
$55
